Indevus Announces FDA Approval Of SUPPRELIN(R)-LA

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that SUPPRELIN(R)-LA (histrelin acetate subcutaneous implant) 50mg has been approved by the U.S. Food and Drug Administration (FDA). SUPPRELIN-LA is indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. The Company will host a conference call and webcast to discuss this announcement on Friday, May 4, 2007, at 9:00 am eastern time (details below). [click link for full article]

Read More: continued here

Filed under: Endocrinology on May 7th, 2007